Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel and gemcitabine with or without olaratumab in first-line metastatic pancreatic cancer
2016-001099-31Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of olaratumab in pancreatic adenocarcinoma (PDAC), pancreatic cancer (PDAC), sponsored by Eli Lilly and Company. Started Jan 2017; status: completed.
02
Drugs
olaratumab
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PDAC)
Beyond the preview
Go deeper on 2016-001099-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001099-31.